Navigation Links
PAREXEL Appoints Leading Biopharmaceutical Marketing Expert Jacque Fisher to Medical Communications Services Executive Team
Date:3/12/2008

BOSTON, March 12 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services organization, has appointed Jacque Fisher as a Vice President and General Manager in the Company's Medical Communications Services business. Ms. Fisher brings more than 20 years of experience in biopharmaceutical industry marketing to PAREXEL. In this position, Ms. Fisher leads a global team of experts who assist clients in translating complex scientific information into integrated communications. She also has responsibility for overall client management and advising biopharmaceutical companies on the effectiveness of their medical communications programs.

"Today's highly regulated marketplace demands unique expertise. Clients increasingly turn to our medical communications team for an evidence-based approach to educate physicians and patients about key points of difference for products and to build a strong knowledge base among key opinion leaders," said Glenn Van Deusen, Corporate Vice President and Worldwide Head of Medical Communications Services, PAREXEL. "We expect our clients to greatly benefit from Ms. Fisher's expertise in providing strategic medical communications programs and in-depth experience with quality standards and regulatory requirements. Her leadership will help PAREXEL continue to meet the evolving medical communications needs of our clients."

"Biopharmaceutical companies must begin strategic planning and execution of medical communications in early phases of clinical development to achieve the greatest market awareness and education about their products," said Ms. Jacque Fisher. "I am pleased to join PAREXEL and work with such a high caliber team of medical communicati
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. PAREXEL International to Present at Lehman Brothers 11th Annual Global Healthcare Conference
2. PAREXEL International to Present at Raymond James 29th Annual Institutional Investors Conference
3. PAREXEL to Present Leading Insights Regarding Key Industry Topics at 20th Annual Drug Information Association EuroMeeting
4. PAREXEL International Announces 2-For-1 Stock Split
5. PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results
6. PAREXEL Names Biopharmaceutical Industry Executive Eduard E. Holdener to Board of Directors
7. PAREXEL Announces Date of Second Quarter Fiscal Year 2008 Earnings Release and Conference Call
8. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
9. PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results
10. PAREXEL Announces Date of First Quarter Fiscal Year 2008 Earnings Release and Conference Call
11. PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how latent viruses ... is the Epstein Barr Virus (EBV), and one of these ... chronic inflammatory disease that destroys the body’s joints. As predicted ... high concentrations of EBV DNA in their bodies (1). ...
(Date:1/15/2014)... Jan. 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") ... with R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , Turkey ... (CIS). Nemonoxacin is a novel antibiotic for the treatment of ...
(Date:1/14/2014)... Calif. , Jan. 14, 2014 As pet owners drew ... doubt many of them wrote: "Take better care of my furry ... even designer clothes and top-brand carrying cases to take the little ... parents might also feel compelled to buy some pricey toys at ...
(Date:1/14/2014)... January 14, 2014 In recent years, ... and methods in product development and promotion has led ... This mistrust, fueled by concerns about the insidious impact ... reports of spectacular fines to the world’s biggest pharmas ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... Immunosyn,Corporation (OTC Bulletin Board: IMYN), a biotechnology firm ... rights to,the biopharmaceutical SF-1019 from its affiliate Argyll ... ending March 31, 2008., For the quarter ... general and administrative expenses and $13,393.00 in interest ...
... 16 InterMune, Inc.,(Nasdaq: ITMN ) today announced ... of InterMune, will present at the Citigroup 2008,Global Healthcare ... 1:30 p.m. EDT., To access a live audio ... log on to the investor relations page of InterMune,s,corporate ...
... May 16 StemCyte Inc. today announced,that Chief Scientific ... a focus on the StemCyte,s Indian joint venture at ... will present during the session on "Stem Cells - ... on Saturday, May 17. His,presentation will include information about ...
Cached Biology Technology:Immunosyn Corporation Files 10-Q 2Immunosyn Corporation Files 10-Q 3StemCyte Chief Scientific Officer to Present Company Overview with Focus on Indian Joint Venture at TiEcon 2008 2
(Date:7/9/2014)... one gene for another in a line of living ... reality within this decade. As with any new technology, ... disease-causing genes in humans, for example--as well as questions ... of those concerns to rest: using gene-editing techniques on ... in the cells. The new results were published July ...
(Date:7/9/2014)... As climate change shifts the geographic ranges in which ... it has on their parasites. Does an increased range ... as well? , Not necessarily, says a team of ... Armand Kuris. In a study published in the ... that for some species, the opposite may happen: Hosts ...
(Date:7/9/2014)... Fla. (July 9, 2014) Emerging fungal pathogens ... other parasitic group, causing population declines of amphibians, ... the University of South Florida published in the ... can acquire behavioral or immunological resistance to a ... declines. , "Acquired resistance is important because ...
Breaking Biology News(10 mins):No extra mutations in modified stem cells, study finds 2No extra mutations in modified stem cells, study finds 3Not at home on the range 2Not at home on the range 3Not at home on the range 4USF study: Amphibians can acquire resistance to deadly fungus 2
... are developing new technologies that combine a laser ... particles such as bacteria, viruses and DNA for ... to food safety. The technologies could bring ... or miniature instruments that perform measurements normally requiring ...
... have no way of predicting which threatened miscarriages will ... we are unable to target attempts to rescue the ... counselling," she said. "This has led to wasteful and ... hospital admissions for bed rest, sexual abstinence, low dose ...
... For the first time, fertility experts have shown that, ... poor oral health can have a significant effect on the ... meeting of the European Society of Human Reproduction and Embryology ... of the same order of magnitude as the effect of ...
Cached Biology News:Laser, electric fields combined for new 'lab-on-chip' technologies 2Laser, electric fields combined for new 'lab-on-chip' technologies 3Researchers can predict accurately the outcome of pregnancies threatening to miscarry 2Gum disease can increase the time it takes to become pregnant 2Gum disease can increase the time it takes to become pregnant 3
Collected from 8-12 week-old New Zealand or Californian rabbits.,Supplied in lyophilized form....
Antibody specific for phosphorylattion of histone H3 that occurs during mitosis. Rabbit polyclonal serum. Antigen: Synthetic peptides derived from histone H3, phosphorylated at serines 10 or 28...
5 minutes from gel band to purified DNA...
...
Biology Products: